Navigation Links
Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Date:6/22/2008

About Lilly

Lilly (NYSE: LLY), a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.co.uk .

P-LLY

This press release contains forward-looking statements about the safety and efficacy of olanzapine long acting injection (LAI) and reflects Lilly's current beliefs. However, as with any investigational pharmaceutical product, there are substantial risks and uncertainties in the process of research, development, regulatory milestones and commercialization. There is no guarantee that olanzapine LAI will be approved for the treatment of schizophrenia or that if approved, it will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(i) Falkai P., Wobrock T., Lieberman J., Glenthoj B.,Gattaz W.F., Moller H.J & Wfsbp Task Force On Treatment Guidelines For Schizophrenia. The World Journal of Biological Psychiatry, 2006; 7(1): 5/40.

(ii) Maxine X. Patel and Anthony S. David. Why aren't depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment (2005) 11: 203-211.

(iii) Kane J.M et al. Guidelines for depot antips
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
2. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
3. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
4. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
7. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
8. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
9. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
10. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... The Bio-Process Systems Alliance (BPSA) is pleased ... (ISUS 2015) will be held July 13-15, 2015, ... primary focus on the promises and hurdles impacting the ... to business and regulatory presentations, ISUS 2015 will examine ... single-use industry as the "go-to" platform in bioprocessing. The ...
(Date:5/27/2015)... Manitoba , May 27, 2015 ... customers, the Canadian International Pharmacy Association (CIPA) ... medications online from licensed Canadian pharmacies. Approximately 64% of ... maintenance medications from a non-U.S. pharmacy due to ... are not covered under their insurance plan.   ...
(Date:5/27/2015)... ANGELES , May 27, 2015  CytRx Corporation ... company specializing in oncology, today announced an upcoming poster ... 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, ... 2015 in Chicago . ... profile we,re seeing in patients who have undergone treatment ...
Breaking Medicine Technology:BPSA's 5th Annual Summit to Provide '2020 Vision' for Single-Use Technologies 2BPSA's 5th Annual Summit to Provide '2020 Vision' for Single-Use Technologies 3Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 2Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 3CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 2CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 3CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 4CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 5
... WIRE)--Jun 27, 2007 - Annals of,Internal Medicine has ... the impact of genistein on bone loss. The ... in Osteopenic,Postmenopausal Women-A Randomized Trial," appears in the ... and efficacy of,genistein for the dietary management of ...
... - Opexa,Therapeutics, Inc. (NASDAQ:OPXA), a company involved ... presented,poster presentations at the 5th International Society ... Cairns, Queensland, Australia,from June 17-20 and at ... for Cellular Therapy (ISCT) in Sydney, Australia ...
Cached Medicine Technology:New Proof of Genistein's Efficacy and Safety for Osteopenia and,Osteoporosis Published in Annals of Internal Medicine 2New Proof of Genistein's Efficacy and Safety for Osteopenia and,Osteoporosis Published in Annals of Internal Medicine 3Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 2Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 3
(Date:5/27/2015)... Rock, AR (PRWEB) May 27, 2015 ... Medix today announce a partnership to provide CMSA's ... Medix community. This collaboration seeks to strengthen the ... measurement through CMSA’s CKP program. The mutually beneficial ... on identifying individual skills of talent in the ...
(Date:5/27/2015)... Mountain View, CA (PRWEB) May 27, 2015 ... Napa Valley will be able to reach for Organic Coconut ... 2015. Coco Libre will be available at VIP areas, artist ... will also be available at area hotels and on festival ... as a partner this year,” said Noa Elan, Director of ...
(Date:5/27/2015)... Meadows, IL (PRWEB) May 27, 2015 ... release of its SonarMD Platform, a first-of-its ... monitoring and managing patients with chronic gastrointestinal ... Kosinski, MD, MBA, the application allows physicians ... visits through the ongoing use of electronic ...
(Date:5/27/2015)... 27, 2015 SmarterSkin, http://www.smarterskindermatology.com , is ... cutting-edge test that makes it easier for patients to find ... , Dr. Sejal Shah is a cosmetic dermatologist based ... to offer the test. This revolutionary DNA test uses 16 ... skin aging: , 1. Firmness and elasticity , ...
(Date:5/27/2015)... CRN International, the radio marketing and promotions ... Financial Officer. , Prinner most recently was Principal of ... financial/operational executive positions at telecom and technology services companies ... and SNET. His accounting and consulting career began ... will be able to tap into his experience of ...
Breaking Medicine News(10 mins):Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2Health News:CRN International Names New Chief Financial Officer 2
... ... ... continuing to offer H1N1 nasal vaccines and H1N1 vaccine shots at four Centegra Primary Care (CPC) ... sites in Huntley, Woodstock, Crystal Lake and McHenry and will be open as follows: , ...
... , LA JOLLA, Calif., Dec. 3 ... Studies unanimously voted to elect three new members during its ... is co-founder and Managing Director of De Novo Ventures in Palo ... in early stage medical device and biotechnology companies. Dotzler founded Medicus ...
... , Research could lead to an ... known to result in cancer and genetic diseases , ... first time observed the movement of a single molecule of ... significantly, they have identified a previously unknown step that they ...
... primates , , THURSDAY, Dec. 3 (HealthDay News) -- A ... a primate study. , The drug, called SPC3649, uses a ... Unlike other antivirals that target the virus itself, the new ... that hepatitis C needs to replicate, the researchers explained. , ...
... , , CHICAGO, Dec. 3 ... medicine, called platelet-rich plasma therapy (PRP), is showing strong ... to a prominent dental researcher and editor of the ... James Rutkowski, DMD, PhD, reported at the recent annual ...
... Deutsches rzteblatt International contains the first scientific presentation ... virus (H1N1/09) in the German-speaking countries since the start ... the Dsseldorf University Hospital retrospectively evaluated data from a ... Dtsch Arztebl Int 2009; 106[47]: 770-6). Their medical-scientific ...
Cached Medicine News:Health News:Centegra H1N1 Vaccination Clinics Continue 2Health News:Centegra H1N1 Vaccination Clinics Continue 3Health News:Centegra H1N1 Vaccination Clinics Continue 4Health News:Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 3Health News:New Hepatitis C Treatment Shows Promise 2Health News:New Hepatitis C Treatment Shows Promise 3Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2
... First Stop absorbable collagen hemostat. FirstStop is ... handling and removal characteristics. It can easily ... fit the wound. FirstStop products are not ... peeled away after hemostasis is achieved. As ...
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: